{"id":"difelikefalin","rwe":[{"pmid":"41708519","year":"2026","title":"Association of pruritus with comorbidities and survival in chronic kidney disease: a narrative review of the pre-difelikefalin era literature.","finding":"","journal":"Renal failure","studyType":"Clinical Study"},{"pmid":"41598433","year":"2026","title":"Uremic Pruritus in Hemodialysis: Mechanisms, Burden, and Emerging Therapies.","finding":"","journal":"Journal of clinical medicine","studyType":"Clinical Study"},{"pmid":"41563679","year":"2026","title":"Reduction of pruritus and depression using longitudinal patient-reported outcome measures in hemodialysis: a quality improvement project.","finding":"","journal":"Journal of patient-reported outcomes","studyType":"Clinical Study"},{"pmid":"41481512","year":"2026","title":"The Efficacy and Safety of Intravenous Difelikefalin for the Treatment of Pruritus in Patients Undergoing Hemodialysis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","finding":"","journal":"Blood purification","studyType":"Clinical Study"},{"pmid":"41436718","year":"2025","title":"Real-world effectiveness and tolerability of difelikefalin over 12 months for hemodialysis-associated pruritus.","finding":"","journal":"International urology and nephrology","studyType":"Clinical Study"}],"_fda":{"id":"1d0f4d9e-7a5e-4320-96ca-da538aec0c2f","set_id":"0c7b81f2-0fd3-47cb-8b0f-185e07f19c87","openfda":{"unii":["0P70AR5BYB"],"route":["INTRAVENOUS"],"rxcui":["2569094","2569100"],"spl_id":["1d0f4d9e-7a5e-4320-96ca-da538aec0c2f"],"brand_name":["Korsuva"],"spl_set_id":["0c7b81f2-0fd3-47cb-8b0f-185e07f19c87"],"package_ndc":["59353-065-01","59353-065-12"],"product_ndc":["59353-065"],"generic_name":["DIFELIKEFALIN"],"product_type":["HUMAN PRESCRIPTION DRUG"],"substance_name":["DIFELIKEFALIN ACETATE"],"manufacturer_name":["Vifor (International), Inc."],"application_number":["NDA214916"],"is_original_packager":[true]},"version":"9","pregnancy":["8.1 Pregnancy Risk Summary The limited human data on use of KORSUVA in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or miscarriage. In animal reproduction studies, intravenous injection of difelikefalin to pregnant rats and rabbits during the period of organogenesis at doses 711 and 10 times the maximum recommended human dose (MRHD), respectively, resulted in no adverse effects in either rats or rabbits (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data In an embryofetal development study, difelikefalin was administered by intravenous injection to pregnant rats at doses of 0.25, 2.5, and 25 mg/kg/day during the period of organogenesis. Difelikefalin was not associated with embryofetal lethality or fetal malformations. Difelikefalin increased the incidences of skeletal variations (wavy ribs and incompletely ossified ribs) at the dose of 25 mg/kg/day (711 times the MRHD based on AUC comparison). In an embryofetal development study, difelikefalin was administered by intravenous injection to pregnant rabbits at doses of 0.025, 0.05, and 0.1 mg/kg/day during the period of organogenesis. Maternal toxicity evidenced by decreased maternal body weight gain was noted in all dose groups. Difelikefalin was not associated with embryofetal lethality or fetal malformations at doses up to 0.1 mg/kg/day (10 times the MRHD based on AUC comparison). In a prenatal and postnatal development study, difelikefalin was administered by intravenous injection to pregnant rats at doses of 0.6, 2.5, and 10 mg/kg/day beginning on gestation day 7 and continuing through lactation day 20. Persisting effects on decreased maternal body weight and/or maternal body weight gain as well as food consumption were noted at doses greater than or equal to 2.5 mg/kg/day (68 times the MRHD based on AUC comparison). No maternal effects were observed at 0.6 mg/kg/day (14 times the MRHD based on AUC comparison). No difelikefalin-related effects on postnatal developmental, neurobehavioral, or reproductive performance of offspring were noted at doses up to 10 mg/kg/day (282 times the MRHD based on AUC comparison)."],"overdosage":["10 OVERDOSAGE Single doses of KORSUVA up to 12 times and multiple doses of KORSUVA up to 5 times the recommended dosage of 0.5 mcg/kg were administered in clinical studies in subjects undergoing HD. A dose-dependent increase in adverse reactions, including dizziness, somnolence, mental status changes, paresthesia, fatigue, hypertension, and vomiting, were observed. In the event of overdosage, provide the appropriate medical attention based on patient's clinical status. Difelikefalin is primarily eliminated by the kidneys with a low plasma protein binding of approximately 23% to 28% in dialysis patients. Hemodialysis for 4 hours using a high-flux dialyzer effectively cleared approximately 70% to 80% of difelikefalin from plasma, and difelikefalin was not detectable in plasma at the end of the second of two dialysis cycles. [see Clinical Pharmacology (12.3) ]."],"description":["11 DESCRIPTION KORSUVA (difelikefalin) is a kappa opioid receptor agonist. Difelikefalin is a synthetic peptide with a single stereoisomer and is present as an acetate salt. Difelikefalin acetate is a white to off-white powder with a molecular formula of C 36 H 53 N 7 O 6 ∙xAcOH (1.0≤ × ≤2.0) and a molecular weight of 679.4 g/mol (mono- isotopic; free base). It is soluble in water. The chemical name of difelikefalin acetate is 4-amino-1-(D-phenylalanyl-D-phenylalanyl-D-leucyl-D-lysyl)piperidine-4-carboxylic acid, acetate salt. The chemical structure is: KORSUVA (difelikefalin) injection is supplied in a single-dose vial containing 65 mcg/1.3 mL (50 mcg/mL) of difelikefalin as a sterile, preservative-free, clear and colorless solution for intravenous injection. KORSUVA is formulated as an isotonic 40 mM acetate buffer solution with an osmolality of 250 to 350 mOsm and a pH of 4.5. Each milliliter of KORSUVA injection contains 50 mcg of difelikefalin (equivalent to an average of 58.3 mcg of difelikefalin acetate), 1.3 mg of acetic acid, 2.5 mg of sodium acetate trihydrate, 7.2 mg of sodium chloride (to adjust tonicity), and water for injection. Chemical Structure"],"how_supplied":["16 HOW SUPPLIED/STORAGE AND HANDLING How Supplied KORSUVA (difelikefalin) injection is supplied as a sterile, clear and colorless solution in 1.3 mL single-dose, glass vials: NDC 59353-065-01: 65 mcg/1.3 mL (50 mcg/mL) single-dose vial NDC 59353-065-12: Carton containing 12 vials Storage and Handling Store vials at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Do not freeze. KORSUVA injection must be administered within 4 hours of syringe preparation; prepared syringes can be stored at ambient temperature 20°C to 25°C (68°F to 77°F) until dosing [see Dosage and Administration (2.2 , 2.3) ] . KORSUVA injection is supplied in a single-dose vial. Any unused drug remaining after injection must be discarded."],"geriatric_use":["8.5 Geriatric Use Of the 848 subjects in the placebo-controlled studies who received KORSUVA, 278 subjects (32.8%) were 65 years of age and older and 98 subjects (11.6%) were 75 years of age and older. No overall differences in safety or effectiveness of KORSUVA have been observed between patients 65 years of age and older and younger adult subjects, with the exception of the incidence of somnolence which was higher in KORSUVA-treated subjects 65 years of age and older (7.0%) than in KORSUVA-treated subjects less than 65 years of age (2.8%), and was comparable in both placebo age groups (3.0% and 2.1%, respectively). No differences in plasma concentrations of KORSUVA were observed between subjects 65 years of age and older and younger adult subjects [see Clinical Pharmacology (12.3) ] ."],"pediatric_use":["8.4 Pediatric Use The safety and effectiveness of KORSUVA in pediatric patients have not been established."],"effective_time":"20250826","clinical_studies":["14 CLINICAL STUDIES The efficacy of KORSUVA was evaluated in two randomized, multicenter, double-blind, placebo-controlled trials (Trial 1 [NCT03422653] and Trial 2 [NCT03636269]) that enrolled a total of 851 subjects 18 years of age and older undergoing HD who had moderate-to-severe pruritus. In both trials, subjects received intravenous bolus injections of KORSUVA 0.5 mcg per kilogram of dry body weight into the venous line of the hemodialysis circuit at the end of each hemodialysis session or placebo three times per week for 12 weeks. In both trials, a 7-day run-in period prior to randomization was used to confirm that each subject had moderate-to-severe pruritus and to establish a baseline itch intensity, as measured by the patient-reported daily 24-hour Worst Itching Intensity Numerical Rating Scale (WI-NRS) scores (0 \"no itch\" to 10 \"worst itch imaginable\"). The mean (SD) baseline WI-NRS score was 7.1 (1.5) in Trial 1 and 7.2 (1.4) in Trial 2. At baseline in Trial 1, 61% of subjects were male, 49% were White, 42% were Black or African American, the mean age was 57 years (range 22 to 88 years), and 40% of subjects were using prior anti-pruritic medications (including sedating antihistamines) and continued the use throughout the trial. At baseline in Trial 2, 58% of subjects were male, 70% were White, 19% were Black or African American, the mean age was 60 years (range 23 to 90 years), and 36% of subjects were using prior anti-pruritic medications (including sedating antihistamines) and continued the use throughout the trial. In each trial, efficacy was assessed based on the proportion of subjects achieving a 4-point or greater improvement (reduction) from baseline in the weekly mean of the daily 24-hour WI-NRS score at Week 12. The results of the KORSUVA trials (Trials 1 and 2) are presented in Table 3 and Figure 1. Table 3. Efficacy Results of Subjects with Moderate-to-Severe CKD-aP Undergoing HD at Week 12 (Trials 1 & 2) Trial 1 Trial 2 KORSUVA 0.5 mcg/kg 3 times weekly N=189 Placebo N=189 KORSUVA 0.5 mcg/kg 3 times weekly N=237 Placebo N=236 Percentage of subjects with ≥4-point improvement from baseline in WI-NRS score 40% 21% 37% 26% Difference from Placebo (95% CI) 19% (9%, 28%) 12% (3%, 20%) Figure 1: Percentage of Subjects with Moderate-to-Severe CKD-aP Undergoing HD with a ≥4-point Improvement from Baseline on the WI-NRS in Trial 1 and Trial 2 Itch reduction was seen by Week 4 and sustained through Week 12. Figure 1"],"pharmacodynamics":["12.2 Pharmacodynamics Difelikefalin exposure-response relationships and the time course of pharmacodynamic response are unknown. Cardiac Electrophysiology At a dose 6 times the recommended dosage, difelikefalin does not prolong the QTc interval to any clinically relevant extent."],"pharmacokinetics":["12.3 Pharmacokinetics The pharmacokinetics of difelikefalin is dose proportional over a single dosage range from 1 to 3 mcg/kg (2 to 6 times the recommended dosage) and multiple intravenous dosage range from 0.5 to 2.5 mcg/kg (1 to 5 times the recommended dosage) in chronic kidney disease patients undergoing HD. Steady-state was reached after the second administered dosage and the mean accumulation ratio was up to 1.6. Distribution The mean volume of distribution of difelikefalin is approximately 238 mL/kg. Difelikefalin binding to human plasma protein in dialysis patients is 23% to 28%. Elimination The half-life of difelikefalin in HD subjects prior to dialysis ranged between 23 and 31 hours. Following administration of radiolabeled difelikefalin, >99% of circulating radioactivity was present in plasma as parent. Hemodialysis reduced the difelikefalin plasma concentrations by 70% to 80% and difelikefalin was not detectable in plasma after 2 dialysis cycles. Metabolism Difelikefalin is not metabolized by cytochrome P450 (CYP) enzymes CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP2D6 or CYP3A observed in human hepatic microsomes or hepatocytes, in vitro. Excretion Following administration of difelikefalin to HD patients, 11% of the dosage was excreted in urine, 59% in feces, and 20% in dialysate fluid. Specific Populations No clinically significant differences in the pharmacokinetics of difelikefalin were observed based on age (25 to 80 years of age), sex, race/ethnicity, or mild-to-moderate hepatic impairment. The effect of severe hepatic impairment on the pharmacokinetics of difelikefalin is unknown [see Use in Specific Populations (8.6) ] . Drug Interaction Studies Clinical Studies No clinical studies evaluating the drug interaction potential of difelikefalin were conducted. In Vitro Studies Cytochrome P450 (CYP) Enzymes: Difelikefalin did not inhibit CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A, or CYP2D6), or induce CYP enzymes (CYP1A2, CYP2B6, or CYP3A) and is not a substrate of CYP450 enzymes (CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP2D6 or CYP3A). Uridine diphosphate (UDP)-glucuronosyl transferase (UGT) Enzymes: Difelikefalin is not an inhibitor of UGT1A3, UGT1A9, or UGT2B7. Transporter Systems: Difelikefalin did not inhibit BCRP, Pgp, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, or, MATE2-K human transporters and is not a substrate of OAT1, OAT2, OAT3, OATP1A2, OCT2, OCT3, LAT1, PEPT1, PEPT2, ASBT, BSEP, MRP2, OATP1B1, OATP1B3, OATP2B1, OCT1, OCTN1, OCTN2, Pgp, BCRP, OSTα/β, MATE1, or, MATE2-K."],"adverse_reactions":["6 ADVERSE REACTIONS The following clinically significant adverse reactions are described elsewhere in the labeling: Dizziness, Somnolence, Mental Status Changes, and Gait Disturbances [see Warnings and Precautions (5.1) ] The most common adverse reactions (incidence ≥2% and ≥1% higher than placebo) were diarrhea, dizziness, nausea, gait disturbances, including falls, hyperkalemia, headache, somnolence, and mental status change. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Vifor (International) Inc. at 1-844-835-8277 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. A total of 1306 subjects undergoing HD who had moderate-to-severe pruritus were treated with KORSUVA in placebo-controlled and uncontrolled Phase 3 clinical trials. Of these, 711 were treated for at least 6 months and 400 were treated for at least one year. Two placebo-controlled Phase 3 trials (Trial 1 and Trial 2), in subjects undergoing HD who had moderate-to-severe pruritus were pooled to evaluate the safety of KORSUVA in comparison to placebo up to 12 weeks. In total, 848 subjects were evaluated (424 in KORSUVA group and 424 in placebo group). The mean age of the subjects was 59 years (range 22 to 88 years), and 59% of the subjects were male. Of the total subjects, 61% were White, 29% were Black or African American, and 5% were Asian. Table 2 summarizes the adverse reactions that occurred at a rate of ≥2% in the KORSUVA group and ≥1% higher than that of the placebo group during the 12-week placebo-controlled period of Trials 1 and 2. The percentage of subjects who discontinued treatment due to any adverse reaction was 2.6% for subjects taking KORSUVA and 0.7% for subjects taking placebo. The most common adverse reactions (≥0.5% of subjects) leading to discontinuation were dizziness (0.9% for KORSUVA and 0.2% for placebo), mental status change (0.7% and 0.2%, respectively), nausea (0.5% and 0%, respectively), and headache (0.5% and 0%, respectively). The percentage of subjects who developed serious adverse reactions was 4.5% in the KORSUVA group and 2.8% in the placebo group. Table 2: Adverse Reactions in ≥ 2% of KORSUVA-Treated Subjects with Moderate-to-Severe CKD-aP Undergoing HD and ≥ 1% Higher Than Placebo in Trials 1 and 2 Adverse Reactions Placebo (N=424) n (%) KORSUVA (N=424) n (%) Diarrhea 24 (5.7) 38 (9.0) Dizziness 16 (3.8) 29 (6.8) Nausea 19 (4.5) 28 (6.6) Gait Disturbances Gait disturbances includes: preferred terms of falls and gait disturbances 23 (5.4) 28 (6.6) Hyperkalemia 15 (3.5) 20 (4.7) Headache 11 (2.6) 19 (4.5) Somnolence 10 (2.4) 18 (4.2) Mental Status Change Mental Status Change includes: preferred terms of confusional state and mental status change. 6 (1.4) 14 (3.3) Description of Selected Adverse Reactions Gait Disturbances, including Falls Gait disturbances, including falls, were reported in 6.6% of subjects receiving KORSUVA compared to 5.4% of subjects who received placebo. Falls were reported as serious adverse reactions in < 1% of subjects receiving KORSUVA and placebo, with one subject discontinuing KORSUVA due to gait disturbance. Dizziness Dizziness was reported in 6.8% of subjects randomized to KORSUVA compared to 3.8% of subjects who received placebo. Dizziness occurred within the first 3 weeks of treatment and was generally transient. Dizziness was serious in 0.2% of KORSUVA-treated subjects compared to 0% of subjects who received placebo and led to discontinuation in 0.9% of KORSUVA-treated subjects compared to 0.2% of subjects who received placebo. Somnolence Somnolence was reported in 4.2% of subjects randomized to receive KORSUVA compared to 2.4% of subjects who received placebo. Somnolence occurred within the first 3 weeks of treatment and tended to subside with continued dosing. Somnolence was serious in 0.2% of KORSUVA-treated subjects compared to 0% of subjects who received placebo. There were no subjects who discontinued KORSUVA due to an adverse reaction of somnolence. Mental Status Change Mental status change (including confusional state) was reported in 3.3% of subjects randomized to receive KORSUVA compared to 1.4% of subjects who received placebo. Most events tended to subside with continued dosing. Mental status change adverse reactions were serious in 1.4% of KORSUVA-treated subjects compared to 0.5% of subjects who received placebo and led to discontinuation in 0.7% of KORSUVA-treated subjects compared to 0.2% of subjects who received placebo. Hyperkalemia Hyperkalemia was found in 4.7% of subjects who received KORSUVA compared to 3.5% of subjects who received placebo. The incidence of hyperkalemia was higher in subjects who took concomitant opioids regardless of treatment and was almost doubled in the KORSUVA group (11.7%) compared to the placebo group (6.2%). The clinical relevance of this is unknown."],"contraindications":["4 CONTRAINDICATIONS None None"],"mechanism_of_action":["12.1 Mechanism of Action KORSUVA is a kappa opioid receptor (KOR) agonist. The relevance of KOR activation to therapeutic effectiveness is not known."],"storage_and_handling":["Storage and Handling Store vials at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Do not freeze. KORSUVA injection must be administered within 4 hours of syringe preparation; prepared syringes can be stored at ambient temperature 20°C to 25°C (68°F to 77°F) until dosing [see Dosage and Administration (2.2 , 2.3) ] . KORSUVA injection is supplied in a single-dose vial. Any unused drug remaining after injection must be discarded."],"clinical_pharmacology":["12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action KORSUVA is a kappa opioid receptor (KOR) agonist. The relevance of KOR activation to therapeutic effectiveness is not known. 12.2 Pharmacodynamics Difelikefalin exposure-response relationships and the time course of pharmacodynamic response are unknown. Cardiac Electrophysiology At a dose 6 times the recommended dosage, difelikefalin does not prolong the QTc interval to any clinically relevant extent. 12.3 Pharmacokinetics The pharmacokinetics of difelikefalin is dose proportional over a single dosage range from 1 to 3 mcg/kg (2 to 6 times the recommended dosage) and multiple intravenous dosage range from 0.5 to 2.5 mcg/kg (1 to 5 times the recommended dosage) in chronic kidney disease patients undergoing HD. Steady-state was reached after the second administered dosage and the mean accumulation ratio was up to 1.6. Distribution The mean volume of distribution of difelikefalin is approximately 238 mL/kg. Difelikefalin binding to human plasma protein in dialysis patients is 23% to 28%. Elimination The half-life of difelikefalin in HD subjects prior to dialysis ranged between 23 and 31 hours. Following administration of radiolabeled difelikefalin, >99% of circulating radioactivity was present in plasma as parent. Hemodialysis reduced the difelikefalin plasma concentrations by 70% to 80% and difelikefalin was not detectable in plasma after 2 dialysis cycles. Metabolism Difelikefalin is not metabolized by cytochrome P450 (CYP) enzymes CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP2D6 or CYP3A observed in human hepatic microsomes or hepatocytes, in vitro. Excretion Following administration of difelikefalin to HD patients, 11% of the dosage was excreted in urine, 59% in feces, and 20% in dialysate fluid. Specific Populations No clinically significant differences in the pharmacokinetics of difelikefalin were observed based on age (25 to 80 years of age), sex, race/ethnicity, or mild-to-moderate hepatic impairment. The effect of severe hepatic impairment on the pharmacokinetics of difelikefalin is unknown [see Use in Specific Populations (8.6) ] . Drug Interaction Studies Clinical Studies No clinical studies evaluating the drug interaction potential of difelikefalin were conducted. In Vitro Studies Cytochrome P450 (CYP) Enzymes: Difelikefalin did not inhibit CYP enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP3A, or CYP2D6), or induce CYP enzymes (CYP1A2, CYP2B6, or CYP3A) and is not a substrate of CYP450 enzymes (CYP1A2, CYP2C19, CYP2C8, CYP2C9, CYP2D6 or CYP3A). Uridine diphosphate (UDP)-glucuronosyl transferase (UGT) Enzymes: Difelikefalin is not an inhibitor of UGT1A3, UGT1A9, or UGT2B7. Transporter Systems: Difelikefalin did not inhibit BCRP, Pgp, OAT1, OAT3, OCT1, OCT2, OATP1B1, OATP1B3, MATE1, or, MATE2-K human transporters and is not a substrate of OAT1, OAT2, OAT3, OATP1A2, OCT2, OCT3, LAT1, PEPT1, PEPT2, ASBT, BSEP, MRP2, OATP1B1, OATP1B3, OATP2B1, OCT1, OCTN1, OCTN2, Pgp, BCRP, OSTα/β, MATE1, or, MATE2-K."],"indications_and_usage":["1 INDICATIONS AND USAGE KORSUVA is indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). KORSUVA is a kappa opioid receptor agonist indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD-aP) in adults undergoing hemodialysis (HD). ( 1 ) Limitation of Use Korsuva has not been studied in patients on peritoneal dialysis and is not recommended for use in this population. ( 1 ) Limitations of Use KORSUVA has not been studied in patients on peritoneal dialysis and is not recommended for use in this population."],"warnings_and_cautions":["5 WARNINGS AND PRECAUTIONS Dizziness, Somnolence, Mental Status Changes, and Gait Disturbances: Dizziness, somnolence, mental status changes, and gait disturbances, including falls, have occurred. Centrally-acting depressant medications, sedating antihistamines, and opioid analgesics should be used with caution during treatment with KORSUVA. ( 5.1 ) Risk of Driving and Operating Machinery: May impair mental or physical abilities. Advise patients not to drive or operate dangerous machinery until the effect of KORSUVA on a patient's ability to drive or operate machinery is known. ( 5.2 ) 5.1 Dizziness, Somnolence, Mental Status Changes, and Gait Disturbances Dizziness, somnolence, mental status changes, and gait disturbances, including falls, have occurred in patients taking KORSUVA and may subside over time with continued treatment [see Adverse Reactions (6.1) ] . In Trial 1 and Trial 2, 17.0% of patients randomized to receive KORSUVA reported at least one of these adverse reactions, compared to 12.0% of patients who received placebo. The incidence of somnolence was higher in KORSUVA-treated subjects 65 years of age and older (7.0%) than in KORSUVA-treated subjects less than 65 years of age (2.8%). Concomitant use of centrally-acting depressant medications, sedating antihistamines and opioid analgesics may increase the likelihood of these adverse reactions and should be used with caution during treatment with KORSUVA. 5.2 Risk of Driving and Operating Machinery Dizziness, somnolence, and mental status changes have occurred in patients taking KORSUVA. KORSUVA may impair the mental or physical abilities needed to perform potentially hazardous activities such as driving a car and operating machinery. Advise patients not to drive or operate dangerous machinery until the effect of KORSUVA on a patient's ability to drive or operate machinery is known ."],"clinical_studies_table":["
Table 3. Efficacy Results of Subjects with Moderate-to-Severe CKD-aP Undergoing HD at Week 12 (Trials 1 & 2)
Trial 1Trial 2
KORSUVA 0.5 mcg/kg 3 times weekly N=189Placebo N=189KORSUVA 0.5 mcg/kg 3 times weekly N=237Placebo N=236
Percentage of subjects with ≥4-point improvement from baseline in WI-NRS score40%21%37%26%
Difference from Placebo (95% CI)19% (9%, 28%)12% (3%, 20%)
"],"nonclinical_toxicology":["13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year carcinogenicity study in rats, difelikefalin was not carcinogenic when administered via subcutaneous injection at doses up to 1.0 mg/kg/day (597 times the MRHD based on AUC comparison). Difelikefalin was not carcinogenic in a 6-month carcinogenicity study in transgenic rasH2 mice at subcutaneous doses up to 30 mg/kg/day. Difelikefalin was negative for genotoxicity in a bacterial reverse mutation assay, an in vitro mammalian chromosomal aberration assay, and an in vivo mouse micronucleus assay. Difelikefalin administered via intravenous injection caused a significant decrease in the number of estrous cycles per 14 days (i.e., prolonged diestrus) in female rats at doses greater than or equal to 2.5 mg/kg/day (56 times the MRHD based on AUC comparison). Difelikefalin had no effects on mating index, fertility index, or any ovarian or uterine parameters in female rats at doses up to 25 mg/kg/day (635 times the MRHD based on AUC comparison). Difelikefalin did not impair male fertility at doses up to 25 mg/kg/day (971 times the MRHD based on AUC comparison)."],"adverse_reactions_table":["
Table 2: Adverse Reactions in ≥ 2% of KORSUVA-Treated Subjects with Moderate-to-Severe CKD-aP Undergoing HD and ≥ 1% Higher Than Placebo in Trials 1 and 2
Adverse ReactionsPlacebo (N=424) n (%)KORSUVA (N=424) n (%)
Diarrhea24 (5.7)38 (9.0)
Dizziness16 (3.8)29 (6.8)
Nausea19 (4.5)28 (6.6)
Gait DisturbancesGait disturbances includes: preferred terms of falls and gait disturbances23 (5.4)28 (6.6)
Hyperkalemia15 (3.5)20 (4.7)
Headache11 (2.6)19 (4.5)
Somnolence10 (2.4)18 (4.2)
Mental Status ChangeMental Status Change includes: preferred terms of confusional state and mental status change.6 (1.4)14 (3.3)
"],"information_for_patients":["17 PATIENT COUNSELING INFORMATION Dizziness, Somnolence, Mental Status Changes, and Gait Disturbances Inform patients that dizziness, somnolence, mental status changes, and gait disturbances, including falls, can occur during treatment with KORSUVA [see Adverse Reactions (6.1) ] . Somnolence is more likely to happen to patients who are age 65 years or older. Inform patients that concomitant treatment with centrally-acting depressants, sedating antihistamines and opioid analgesics may increase the likelihood of these adverse reactions and these medications should be used with caution during treatment with KORSUVA [see Warnings and Precautions (5.1) ] . Driving or Operating Machinery Inform patients that KORSUVA may impair the ability to perform potentially hazardous activities such as driving a car or operating heavy machinery. Advise patients not to drive or operate machinery until they know how they will react to KORSUVA [see Warnings and Precautions (5.2) ]."],"spl_unclassified_section":["Manufactured for and marketed by Vifor (International) Inc., Rechenstrasse 37, 9014 St. Gallen, Switzerland"],"dosage_and_administration":["2 DOSAGE AND ADMINISTRATION Recommended dosage is 0.5 mcg/kg. ( 2.1 ) Administer by intravenous bolus injection into the venous line of the dialysis circuit at the end of each HD treatment. ( 2.1 ) Do not mix or dilute KORSUVA prior to administration. ( 2.2 ) Administer within 4 hours of syringe preparation. ( 2.3 ) See full prescribing information for additional recommendations on preparation and administration of KORSUVA. ( 2.2 , 2.3 ) 2.1 Dosage The recommended dosage of KORSUVA is 0.5 mcg/kg administered by intravenous bolus injection into the venous line of the dialysis circuit at the end of each HD treatment [see Dosage and Administration (2.3) ] . If a regularly scheduled HD treatment is missed, resume KORSUVA at the end of the next HD treatment. 2.2 Preparation Instructions Do not mix or dilute KORSUVA prior to administration. Inspect KORSUVA for particulate matter and discoloration prior to administration. The solution should be clear and colorless. Do not use KORSUVA vials if particulate matter or discoloration is observed. KORSUVA is supplied in a single-dose vial. Discard any unused product. Injection volume to be administered is determined by patient's target dry body weight in kilograms (one patient may use less than the full contents of the vial or use more than one vial). See Table 1 . Table 1. KORSUVA Injection Volumes Based on Target Dry Body Weight Target Dry Body Weight Range (kg) Injection Volume (mL) Total Injection Volume (mL) = Patient Target Dry Body Weight (kg) x 0.01, rounded to the nearest tenth (0.1 mL). For patient target dry body weight outside of the ranges in Table 1, use this formula. 36 – 44 0.4 45 – 54 0.5 55 – 64 0.6 65 – 74 0.7 75 – 84 0.8 85 – 94 0.9 95 – 104 1 105 – 114 1.1 115 – 124 1.2 125 – 134 1.3 135 – 144 1.4 145 – 154 1.5 155 – 164 1.6 165 – 174 1.7 175 – 184 1.8 185 – 194 1.9 195 – 204 2 2.3 Administration Instructions KORSUVA is removed by the dialyzer membrane and must be administered after blood is no longer circulating through the dialyzer. Administer KORSUVA by intravenous bolus injection into the venous line of the dialysis circuit at the end of each HD session. The dose may be given either during or after rinse back of the dialysis circuit. If the dose is given after rinse back, administer KORSUVA into the venous line followed by at least 10 mL of normal saline flush. If the dose is given during rinse back, no additional normal saline is needed to flush the line. The dose must be administered within 4 hours of the syringe preparation. Discard any unused product."],"spl_product_data_elements":["Korsuva difelikefalin DIFELIKEFALIN ACETATE DIFELIKEFALIN"],"dosage_forms_and_strengths":["3 DOSAGE FORMS AND STRENGTHS Injection: 65 mcg/1.3 mL (50 mcg/mL) of difelikefalin as a clear, colorless solution in a single-dose glass vial. Injection : 65 mcg /1.3 mL (50 mcg/mL) of difelikefalin ( 3 )"],"use_in_specific_populations":["8 USE IN SPECIFIC POPULATIONS Severe Hepatic Impairment: Not recommended in patients with severe hepatic impairment. ( 8.6 ) 8.1 Pregnancy Risk Summary The limited human data on use of KORSUVA in pregnant women are not sufficient to evaluate a drug-associated risk for major birth defects or miscarriage. In animal reproduction studies, intravenous injection of difelikefalin to pregnant rats and rabbits during the period of organogenesis at doses 711 and 10 times the maximum recommended human dose (MRHD), respectively, resulted in no adverse effects in either rats or rabbits (see Data ) . The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. Data Animal Data In an embryofetal development study, difelikefalin was administered by intravenous injection to pregnant rats at doses of 0.25, 2.5, and 25 mg/kg/day during the period of organogenesis. Difelikefalin was not associated with embryofetal lethality or fetal malformations. Difelikefalin increased the incidences of skeletal variations (wavy ribs and incompletely ossified ribs) at the dose of 25 mg/kg/day (711 times the MRHD based on AUC comparison). In an embryofetal development study, difelikefalin was administered by intravenous injection to pregnant rabbits at doses of 0.025, 0.05, and 0.1 mg/kg/day during the period of organogenesis. Maternal toxicity evidenced by decreased maternal body weight gain was noted in all dose groups. Difelikefalin was not associated with embryofetal lethality or fetal malformations at doses up to 0.1 mg/kg/day (10 times the MRHD based on AUC comparison). In a prenatal and postnatal development study, difelikefalin was administered by intravenous injection to pregnant rats at doses of 0.6, 2.5, and 10 mg/kg/day beginning on gestation day 7 and continuing through lactation day 20. Persisting effects on decreased maternal body weight and/or maternal body weight gain as well as food consumption were noted at doses greater than or equal to 2.5 mg/kg/day (68 times the MRHD based on AUC comparison). No maternal effects were observed at 0.6 mg/kg/day (14 times the MRHD based on AUC comparison). No difelikefalin-related effects on postnatal developmental, neurobehavioral, or reproductive performance of offspring were noted at doses up to 10 mg/kg/day (282 times the MRHD based on AUC comparison). 8.2 Lactation Risk Summary There are no data regarding the presence of KORSUVA in human milk or effects on the breastfed infant or on milk production. Studies in rats showed difelikefalin was transferred into the milk in lactating rats. When a drug is present in animal milk, it is likely that the drug will be present in human milk. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for KORSUVA and any potential adverse effects on the breastfed child from KORSUVA or from the underlying maternal condition. Data Animal Data Difelikefalin was administered to lactating rats by intravenous injection at doses of 0.6, 2.5, or 10 mg/kg/day from gestation day 7 through lactation day 14. Difelikefalin was detected in the milk of the lactating rats with the concentration ratio for milk:plasma of 0.04 to 0.05 across the doses. There was no measurable difelikefalin in the plasma of nursing pups. 8.4 Pediatric Use The safety and effectiveness of KORSUVA in pediatric patients have not been established. 8.5 Geriatric Use Of the 848 subjects in the placebo-controlled studies who received KORSUVA, 278 subjects (32.8%) were 65 years of age and older and 98 subjects (11.6%) were 75 years of age and older. No overall differences in safety or effectiveness of KORSUVA have been observed between patients 65 years of age and older and younger adult subjects, with the exception of the incidence of somnolence which was higher in KORSUVA-treated subjects 65 years of age and older (7.0%) than in KORSUVA-treated subjects less than 65 years of age (2.8%), and was comparable in both placebo age groups (3.0% and 2.1%, respectively). No differences in plasma concentrations of KORSUVA were observed between subjects 65 years of age and older and younger adult subjects [see Clinical Pharmacology (12.3) ] . 8.6 Hepatic Impairment The influence of mild-to-moderate hepatic impairment on the pharmacokinetics of KORSUVA was evaluated in a population pharmacokinetic analysis which concluded that no KORSUVA dosage adjustments are needed in these populations [see Clinical Pharmacology (12.3) ] . The influence of severe hepatic impairment on the pharmacokinetics of KORSUVA in subjects undergoing HD has not been evaluated; therefore, use of KORSUVA in this population is not recommended."],"dosage_and_administration_table":["
Table 1. KORSUVA Injection Volumes Based on Target Dry Body Weight
Target Dry Body Weight Range (kg)Injection Volume (mL)Total Injection Volume (mL) = Patient Target Dry Body Weight (kg) x 0.01, rounded to the nearest tenth (0.1 mL). For patient target dry body weight outside of the ranges in Table 1, use this formula.
36 – 440.4
45 – 540.5
55 – 640.6
65 – 740.7
75 – 840.8
85 – 940.9
95 – 1041
105 – 1141.1
115 – 1241.2
125 – 1341.3
135 – 1441.4
145 – 1541.5
155 – 1641.6
165 – 1741.7
175 – 1841.8
185 – 1941.9
195 – 2042
"],"package_label_principal_display_panel":["PRINCIPAL DISPLAY PANEL - 1.3 mL Vial Label NDC 59353-065-01 Store at 20°C to 25°C (68°F to 77°F) Rx only KORSUVA ™ (difelikefalin) Injection 65 mcg/1.3 mL (50 mcg/mL) For Intravenous Use Only 1.3 mL Single-dose Vial. Discard unused portion Mfd. for Vifor (International) Inc., Rechenstrasse 37, 9014 St. Gallen, Switzerland. Made in France. 3102942-01 48307/16/25 PRINCIPAL DISPLAY PANEL - 1.3 mL Vial Label","PRINCIPAL DISPLAY PANEL - 1.3 mL Tray Carton NDC 59353-065-12 Rx only KORSUVA ™ (difelikefalin) Injection 65 mcg/1.3 mL (50 mcg/mL) For Intravenous Use after Hemodialysis Single-dose vial. Discard unused portion. Store at 20°C to 25°C (68°F to 77°F), excursions permitted to 15°C to 30°C (59°F to 86°F) [see USP Controlled Room Temperature]. Do not freeze. Sterile, preservative-free solution. 12 x 1.3 mL Single-dose Vials PRINCIPAL DISPLAY PANEL - 1.3 mL Tray Carton"],"carcinogenesis_and_mutagenesis_and_impairment_of_fertility":["13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a 2-year carcinogenicity study in rats, difelikefalin was not carcinogenic when administered via subcutaneous injection at doses up to 1.0 mg/kg/day (597 times the MRHD based on AUC comparison). Difelikefalin was not carcinogenic in a 6-month carcinogenicity study in transgenic rasH2 mice at subcutaneous doses up to 30 mg/kg/day. Difelikefalin was negative for genotoxicity in a bacterial reverse mutation assay, an in vitro mammalian chromosomal aberration assay, and an in vivo mouse micronucleus assay. Difelikefalin administered via intravenous injection caused a significant decrease in the number of estrous cycles per 14 days (i.e., prolonged diestrus) in female rats at doses greater than or equal to 2.5 mg/kg/day (56 times the MRHD based on AUC comparison). Difelikefalin had no effects on mating index, fertility index, or any ovarian or uterine parameters in female rats at doses up to 25 mg/kg/day (635 times the MRHD based on AUC comparison). Difelikefalin did not impair male fertility at doses up to 25 mg/kg/day (971 times the MRHD based on AUC comparison)."]},"tags":[{"label":"Kappa Opioid Receptor Agonist","category":"class"},{"label":"Small Molecule","category":"modality"},{"label":"Kappa-type opioid receptor","category":"target"},{"label":"OPRK1","category":"gene"},{"label":"V03AX04","category":"atc"},{"label":"Intravenous","category":"route"},{"label":"Injection","category":"form"},{"label":"LOE Approaching","category":"status"},{"label":"Pruritus associated with chronic kidney disease (CKD-aP)","category":"indication"},{"label":"Vifor Intl","category":"company"},{"label":"Approved 2020s","category":"decade"}],"phase":"marketed","safety":{"boxedWarnings":[],"safetySignals":[{"date":"","signal":"DIZZINESS","source":"FDA FAERS","actionTaken":"42 reports"},{"date":"","signal":"SOMNOLENCE","source":"FDA FAERS","actionTaken":"35 reports"},{"date":"","signal":"FALL","source":"FDA FAERS","actionTaken":"34 reports"},{"date":"","signal":"DRUG INEFFECTIVE","source":"FDA FAERS","actionTaken":"23 reports"},{"date":"","signal":"MENTAL STATUS CHANGES","source":"FDA FAERS","actionTaken":"23 reports"},{"date":"","signal":"DEATH","source":"FDA FAERS","actionTaken":"22 reports"},{"date":"","signal":"CONFUSIONAL STATE","source":"FDA FAERS","actionTaken":"18 reports"},{"date":"","signal":"NAUSEA","source":"FDA FAERS","actionTaken":"18 reports"},{"date":"","signal":"HALLUCINATION","source":"FDA FAERS","actionTaken":"16 reports"},{"date":"","signal":"ASTHENIA","source":"FDA FAERS","actionTaken":"15 reports"}],"commonSideEffects":[{"effect":"Diarrhea","drugRate":"9.0%","severity":"common","_validated":true},{"effect":"Dizziness","drugRate":"6.8%","severity":"common","_validated":true},{"effect":"Nausea","drugRate":"6.6%","severity":"common","_validated":true},{"effect":"Gait Disturbances","drugRate":"6.6%","severity":"common","_validated":true},{"effect":"Hyperkalemia","drugRate":"4.7%","severity":"common","_validated":true},{"effect":"Somnolence","drugRate":"4.2%","severity":"common","_validated":true},{"effect":"Mental Status Change","drugRate":"3.3%","severity":"common","_validated":true},{"effect":"Headache","drugRate":"4.5%","severity":"common","_validated":true},{"effect":"Falls","drugRate":"reported","severity":"unknown"},{"effect":"Confusional state","drugRate":"reported","severity":"unknown"}],"specialPopulations":{"Pregnancy":"The limited human data on use of KORSUVA in pregnant women are not sufficient to evaluate drug-associated risk for major birth defects or miscarriage. In animal reproduction studies, intravenous injection of difelikefalin to pregnant rats and rabbits during the period of organogenesis at doses 711 and 10 times the maximum recommended human dose (MRHD), respectively, resulted in no adverse effects in either rats or rabbits (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively.","Geriatric use":"Of the 848 subjects in the placebo-controlled studies who received KORSUVA, 278 subjects (32.8%) were 65 years of age and older and 98 subjects (11.6%) were 75 years of age and older. No overall differences in safety or effectiveness of KORSUVA have been observed between patients 65 years of age and older and younger adult subjects, with the exception of the incidence of somnolence which was higher in KORSUVA-treated subjects 65 years of age and older (7.0%) than in KORSUVA-treated subjects less than 65 years of age (2.1%).","Paediatric use":"The safety and effectiveness of KORSUVA in pediatric patients have not been established.","Hepatic impairment":"Not recommended in patients with severe hepatic impairment."}},"trials":[],"aliases":[],"company":"Vifor Intl","patents":[{"applNo":"N214916","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2027","useCode":"U-3204","territory":"US","drugProduct":true,"patentNumber":"10793596","drugSubstance":true},{"applNo":"N214916","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2027","useCode":"U-3204","territory":"US","drugProduct":false,"patentNumber":"10138270","drugSubstance":false},{"applNo":"N214916","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2027","useCode":"U-3204","territory":"US","drugProduct":false,"patentNumber":"10017536","drugSubstance":true},{"applNo":"N214916","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2027","useCode":"U-3204","territory":"US","drugProduct":false,"patentNumber":"9359399","drugSubstance":false},{"applNo":"N214916","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2027","useCode":"U-3204","territory":"US","drugProduct":false,"patentNumber":"9334305","drugSubstance":false},{"applNo":"N214916","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2027","useCode":"U-3204","territory":"US","drugProduct":true,"patentNumber":"8536131","drugSubstance":true},{"applNo":"N214916","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2027","useCode":"U-3204","territory":"US","drugProduct":false,"patentNumber":"8486894","drugSubstance":false},{"applNo":"N214916","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2027","useCode":"U-3204","territory":"US","drugProduct":false,"patentNumber":"8236766","drugSubstance":false},{"applNo":"N214916","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2027","useCode":"U-3204","territory":"US","drugProduct":false,"patentNumber":"8217007","drugSubstance":false},{"applNo":"N214916","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2027","useCode":"U-3204","territory":"US","drugProduct":true,"patentNumber":"7727963","drugSubstance":true},{"applNo":"N214916","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2027","useCode":"U-3204","territory":"US","drugProduct":true,"patentNumber":"7713937","drugSubstance":true},{"applNo":"N214916","source":"FDA Orange Book","status":"Active","expires":"Nov 12, 2027","useCode":"U-3204","territory":"US","drugProduct":true,"patentNumber":"7402564","drugSubstance":true}],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=DIFELIKEFALIN","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:49:27.985591+00:00"},"patents":{"url":"","method":"deterministic","source":"FDA Orange Book","rawText":"","confidence":1,"sourceType":"fda_orange_book","retrievedAt":"2026-04-20T00:49:24.310268+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:49:33.144999+00:00"},"regulatory.eu":{"url":"","method":"api_direct","source":"European Medicines Agency","rawText":"","confidence":1,"sourceType":"ema_api","retrievedAt":"2026-04-20T00:49:28.058034+00:00"},"regulatory.us":{"url":"","method":"api_direct","source":"FDA Drugs@FDA","rawText":"","confidence":1,"sourceType":"fda_drugsfda","retrievedAt":"2026-04-20T00:49:22.531394+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIFELIKEFALIN","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:49:33.612875+00:00"},"administration.route":{"url":"","method":"deterministic","source":"FDA Label","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:22.002362+00:00"},"safety.boxedWarnings":{"url":"","method":"deterministic","source":"FDA Label (no boxed warning)","rawText":"","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:22.002389+00:00"},"safety.safetySignals":{"url":"https://api.fda.gov/drug/event.json","method":"api_direct","source":"FDA FAERS","rawText":"","confidence":1,"sourceType":"fda_faers","retrievedAt":"2026-04-20T00:49:35.124184+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Kappa opioid receptor agonist","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:49:34.695673+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL3989915/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:49:34.353774+00:00"},"regulatory.fda_application":{"url":"","method":"deterministic","source":"FDA Label","rawText":"NDA214916","confidence":1,"sourceType":"fda_label","retrievedAt":"2026-04-20T00:49:22.002393+00:00"}},"allNames":"korsuva","offLabel":[],"synonyms":["difelikefalin","difelikefalin acetate","korsuva","CR845","FE202845","MR13A9","kapruvia"],"timeline":[{"date":"2021-01-01","type":"neutral","source":"FDA Orange Book","milestone":"Rights transferred from CARA THERAPEUTICS INC to Vifor Intl"},{"date":"2021-08-23","type":"positive","source":"DrugCentral","milestone":"FDA approval (Cara Therapeutics Inc)"},{"date":"2022-04-25","type":"positive","source":"DrugCentral","milestone":"EMA approval (Vifor Fresenius Medical Care Renal Pharma France)"},{"date":"2026-08-23","type":"negative","source":"FDA Orange Book","milestone":"New Chemical Entity exclusivity expires"},{"date":"2027-11-12","type":"negative","source":"FDA Orange Book","milestone":"Substance patent 10793596 expires"}],"aiSummary":"Korsuva (DIFELIKEFALIN) is a small molecule kappa opioid receptor agonist developed by CARA THERAPEUTICS INC and currently owned by Vifor Intl. It was FDA approved in 2021 for the treatment of pruritus associated with chronic kidney disease (CKD-aP). Korsuva works by activating the kappa-type opioid receptor, providing relief from itching. It is a patented medication with no generic manufacturers available. Key safety considerations include its mechanism of action, which may have implications for patients with a history of substance abuse.","approvals":[{"date":"2021-08-23","orphan":false,"company":"CARA THERAPEUTICS INC","regulator":"FDA"},{"date":"2022-04-25","orphan":false,"company":"VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE","regulator":"EMA"}],"brandName":"Korsuva","ecosystem":[{"indication":"Pruritus associated with chronic kidney disease (CKD-aP)","otherDrugs":[],"globalPrevalence":850000000}],"mechanism":{"target":"Kappa-type opioid receptor","novelty":"Follow-on","targets":[{"gene":"OPRK1","source":"DrugCentral","target":"Kappa-type opioid receptor","protein":"Kappa-type opioid receptor"}],"moaClass":"Opioid kappa Receptor Agonists","modality":"Small Molecule","drugClass":"Kappa Opioid Receptor Agonist","explanation":"KORSUVA is kappa opioid receptor (KOR) agonist. The relevance of KOR activation to therapeutic effectiveness is not known.","oneSentence":"Korsuva works by activating the kappa-type opioid receptor, which helps to reduce itching.","technicalDetail":"Korsuva (DIFELIKEFALIN) is a kappa opioid receptor agonist that binds to the kappa-type opioid receptor, activating G-protein coupled signaling pathways and modulating neurotransmitter release, ultimately leading to the reduction of pruritus."},"commercial":{"launchDate":"2021","_launchSource":"DrugCentral (FDA 2021-08-23, CARA THERAPEUTICS INC)"},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5470","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=DIFELIKEFALIN","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=DIFELIKEFALIN","fields":["publications"],"source":"PubMed/NCBI"},{"id":4,"url":"https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files","fields":["patents","exclusivity","genericManufacturers"],"source":"FDA Orange Book"}],"_emaChecked":true,"_enrichedAt":"2026-03-30T10:35:41.910616","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:49:37.663339+00:00","fieldsConflicting":0,"overallConfidence":0.95},"biosimilars":[],"competitors":[{"drugName":"cobicistat","drugSlug":"cobicistat","fdaApproval":"2012-08-27","patentExpiry":"Sep 3, 2029","patentStatus":"Patent protected","relationship":"same-class"}],"exclusivity":[{"code":"NCE","date":"Aug 23, 2026"}],"genericName":"difelikefalin","indications":{"approved":[{"name":"Pruritus associated with chronic kidney disease (CKD-aP)","source":"DrugCentral","snomedId":707151000,"regulator":"FDA","eligibility":"Adults undergoing hemodialysis (HD), age not specified, CKD-aP stage not specified","usPrevalence":37000000,"globalPrevalence":850000000,"prevalenceMethod":"curated","prevalenceSource":"Lancet, 2023"}],"offLabel":[],"pipeline":[]},"currentOwner":"Vifor Intl","drugCategory":"loe-approaching","labelChanges":[],"relatedDrugs":[{"drugId":"cobicistat","brandName":"cobicistat","genericName":"cobicistat","approvalYear":"2012","relationship":"same-class"}],"trialDetails":[{"nctId":"NCT06593392","phase":"PHASE2","title":"Safety and Tolerability of Difelikefalin in Adolescents on Haemodialysis With Moderate-to-Severe Pruritus","status":"RECRUITING","sponsor":"Vifor Fresenius Medical Care Renal Pharma","startDate":"2026-04-09","conditions":["Pruritus","Chronic Kidney Diseases"],"enrollment":18,"completionDate":"2029-08-15"},{"nctId":"NCT05885737","phase":"PHASE3","title":"Phase 3 Study of Difelikefalin in Haemodialysis Chinese Adult Subjects With Moderate-to-Severe Pruritus","status":"COMPLETED","sponsor":"Vifor Fresenius Medical Care Renal Pharma","startDate":"2023-05-18","conditions":["Uremic Pruritus"],"enrollment":260,"completionDate":"2024-09-25"},{"nctId":"NCT05885763","phase":"PHASE1","title":"Pharmacokinetics of Intravenous Difelikefalin in Chinese Adult Subjects on Haemodialysis","status":"COMPLETED","sponsor":"Vifor Fresenius Medical Care Renal Pharma","startDate":"2023-06-26","conditions":["End Stage Renal Disease on Hemodialysis"],"enrollment":30,"completionDate":"2023-10-09"},{"nctId":"NCT05978063","phase":"PHASE2,PHASE3","title":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica","status":"TERMINATED","sponsor":"Cara Therapeutics, Inc.","startDate":"2023-08-01","conditions":["Pruritus","Notalgia Paresthetica"],"enrollment":214,"completionDate":"2024-05-07"},{"nctId":"NCT05356403","phase":"PHASE3","title":"CR845-310302: A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus","status":"TERMINATED","sponsor":"Cara Therapeutics, Inc.","startDate":"2022-08-26","conditions":["Chronic Kidney Diseases","Pruritus"],"enrollment":105,"completionDate":"2024-02-26"},{"nctId":"NCT05342623","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of Difelikefalin in Advanced Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus","status":"TERMINATED","sponsor":"Cara Therapeutics, Inc.","startDate":"2022-05-17","conditions":["Chronic Kidney Diseases","Pruritus"],"enrollment":286,"completionDate":"2024-02-29"},{"nctId":"NCT05387707","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin as Adjunct Therapy to a Topical Corticosteroid for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis","status":"TERMINATED","sponsor":"Cara Therapeutics, Inc.","startDate":"2022-08-16","conditions":["Pruritus","Atopic Dermatitis"],"enrollment":287,"completionDate":"2024-02-02"},{"nctId":"NCT03617536","phase":"PHASE2","title":"A Study to Evaluate the Safety and Efficacy of CR845 in Chronic Kidney Disease Patients With Moderate-to-Severe Pruritus","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","startDate":"2018-07-05","conditions":["Chronic Kidney Diseases","Pruritus"],"enrollment":269,"completionDate":"2019-11-14"},{"nctId":"NCT03995212","phase":"PHASE2","title":"Study to Evaluate the Safety and Efficacy of Oral CR845 (Difelikefalin) in Patients With Primary Biliary Cholangitis (PBC) and Moderate-to-Severe Pruritus","status":"TERMINATED","sponsor":"Cara Therapeutics, Inc.","startDate":"2019-06-25","conditions":["Cholestatic Pruritus"],"enrollment":14,"completionDate":"2022-06-29"},{"nctId":"NCT04706975","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Notalgia Paresthetica (KOMFORT)","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","startDate":"2021-01-11","conditions":["Pruritus","Notalgia Paresthetica"],"enrollment":126,"completionDate":"2022-06-30"},{"nctId":"NCT05533008","phase":"PHASE1","title":"CR845-100303: Study to Assess the Potential of Physical Withdrawal From Intravenous CR845 (Difelikefalin) in Hemodialysis Patients","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","startDate":"2019-12-31","conditions":["Hemodialysis"],"enrollment":35,"completionDate":"2020-06-11"},{"nctId":"NCT05031546","phase":"","title":"Intermediate-Size Patient Population Expanded Access Program for Intravenous Difelikefalin","status":"APPROVED_FOR_MARKETING","sponsor":"Cara Therapeutics, Inc.","startDate":"","conditions":["Uremic Pruritus"],"enrollment":0,"completionDate":""},{"nctId":"NCT03636269","phase":"PHASE3","title":"CR845-CLIN3103: A Global Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","isPivotal":true,"startDate":"2018-07-17","conditions":["Uremic Pruritus"],"enrollment":473,"completionDate":"2020-03-30"},{"nctId":"NCT03422653","phase":"PHASE3","title":"A Study to Evaluate the Safety and Efficacy of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus (KALM-1)","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","isPivotal":true,"startDate":"2018-02-20","conditions":["Uremic Pruritus"],"enrollment":378,"completionDate":"2020-03-26"},{"nctId":"NCT04018027","phase":"PHASE2","title":"Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","startDate":"2019-06-29","conditions":["Pruritus","Atopic Dermatitis"],"enrollment":401,"completionDate":"2021-04-01"},{"nctId":"NCT03998163","phase":"PHASE3","title":"CR845-CLIN3105: A Study to Evaluate the Safety and Effectiveness of CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","startDate":"2019-05-06","conditions":["Uremic Pruritus"],"enrollment":222,"completionDate":"2020-03-06"},{"nctId":"NCT03281538","phase":"PHASE3","title":"Extension Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","startDate":"2017-08-14","conditions":["Uremic Pruritus"],"enrollment":288,"completionDate":"2020-02-11"},{"nctId":"NCT02944448","phase":"PHASE2","title":"A Study Evaluating Pain Relief and Safety of Orally Administered CR845 in Patients With Osteoarthritis of Hip or Knee","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","startDate":"2016-09","conditions":["Osteoarthritis, Hip","Osteoarthritis, Knee","Arthritis","Joint Diseases","Musculoskeletal Diseases","Rheumatic Diseases"],"enrollment":761,"completionDate":"2017-06"},{"nctId":"NCT02858726","phase":"PHASE2,PHASE3","title":"Study to Evaluate IV CR845 in Hemodialysis Patients With Moderate-to-Severe Pruritus","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","startDate":"2016-06","conditions":["Uremic Pruritus"],"enrollment":226,"completionDate":"2017-03-14"},{"nctId":"NCT04019574","phase":"PHASE1","title":"Study to Investigate the Effects of Single Intravenous Doses of Difelikefalin (CR845) on the QTc Interval in Healthy Subjects","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","startDate":"2019-06-20","conditions":["Healthy"],"enrollment":57,"completionDate":"2019-10-29"},{"nctId":"NCT03947970","phase":"PHASE1","title":"Study to Evaluate the Pharmacokinetics and Metabolism of [14C] CR845 (Difelikefalin) in Patients With End Stage Renal Disease on Hemodialysis and in Healthy Subjects","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","startDate":"2019-01-17","conditions":["Hemodialysis","Healthy"],"enrollment":12,"completionDate":"2019-04-06"},{"nctId":"NCT02542384","phase":"PHASE2,PHASE3","title":"A Study Evaluating the Overall Pain Relief and Safety of Intravenous (IV) CR845 in Patients Undergoing Abdominal Surgery","status":"COMPLETED","sponsor":"Cara Therapeutics, Inc.","startDate":"2015-09","conditions":["Post Abdominal Surgery Pain"],"enrollment":451,"completionDate":"2018-06"}],"_emaApprovals":[{"date":"2022-04-25","status":"Authorised","company":"VIFOR FRESENIUS MEDICAL CARE RENAL PHARMA FRANCE"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"pivotalTrials":["NCT03422653","NCT03636269"],"administration":{"route":"Intravenous","formulation":"Injection","formulations":[{"form":"INJECTION, SOLUTION","route":"INTRAVENOUS","productName":"Korsuva"}]},"_patentsChecked":true,"crossReferences":{"MMSL":"349719","NDDF":"018837","UNII":"NA1U919MRO","VANDF":"4041254","INN_ID":"10179","RXNORM":"2569089","UMLSCUI":"C4519744","chemblId":"CHEMBL3989915","ChEMBL_ID":"CHEMBL3989915","KEGG_DRUG":"D11111","DRUGBANK_ID":"DB11938","PUBCHEM_CID":"24794466","IUPHAR_LIGAND_ID":"9044","SECONDARY_CAS_RN":"1024829-44-4","MESH_SUPPLEMENTAL_RECORD_UI":"C000657129"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"2021-","companyName":"Cara Therapeutics Inc","relationship":"Original Developer"},{"period":"present","companyName":"Vifor Intl","relationship":"Current Owner"},{"period":"2022","companyName":"Vifor Fresenius Medical Care Renal Pharma France","relationship":"EMA Licensee"}],"publicationCount":110,"therapeuticAreas":["Neuroscience"],"_revenueScrapedAt":"2026-03-31 13:12:35.735273+00","atcClassification":{"source":"DrugCentral","atcCode":"V03AX04","allCodes":["V03AX04"]},"biosimilarFilings":[],"originalDeveloper":"Cara Therapeutics Inc","recentPublications":[{"date":"2026 Dec","pmid":"41708519","title":"Association of pruritus with comorbidities and survival in chronic kidney disease: a narrative review of the pre-difelikefalin era literature.","journal":"Renal failure"},{"date":"2026 Jan 8","pmid":"41598433","title":"Uremic Pruritus in Hemodialysis: Mechanisms, Burden, and Emerging Therapies.","journal":"Journal of clinical medicine"},{"date":"2026 Jan 21","pmid":"41563679","title":"Reduction of pruritus and depression using longitudinal patient-reported outcome measures in hemodialysis: a quality improvement project.","journal":"Journal of patient-reported outcomes"},{"date":"2026 Jan 2","pmid":"41481512","title":"The Efficacy and Safety of Intravenous Difelikefalin for the Treatment of Pruritus in Patients Undergoing Hemodialysis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","journal":"Blood purification"},{"date":"2025 Dec 23","pmid":"41436718","title":"Real-world effectiveness and tolerability of difelikefalin over 12 months for hemodialysis-associated pruritus.","journal":"International urology and nephrology"}],"companionDiagnostics":[],"genericManufacturers":0,"_genericFilersChecked":true,"genericManufacturerList":[],"status":"approved","companyName":"Vifor Intl","companyId":"vifor-intl","modality":"Recombinant protein","firstApprovalDate":"2021","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-08-23T00:00:00.000Z","mah":"VIFOR INTL","brand_name_local":null,"application_number":"NDA214916"},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":"2021-08-23T00:00:00.000Z","mah":"CARA THERAPEUTICS INC","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"BR","regulator":"ANVISA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MX","regulator":"COFEPRIS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AR","regulator":"ANMAT","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TR","regulator":"TITCK","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IN","regulator":"CDSCO","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TH","regulator":"FDA-TH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"MY","regulator":"NPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"PH","regulator":"FDA-PH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"CO","regulator":"INVIMA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"ZA","regulator":"SAHPRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"TW","regulator":"TFDA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"HK","regulator":"DH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"IL","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"SG","regulator":"HSA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AE","regulator":"MOH","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"KR","regulator":"MFDS","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"AU","regulator":"TGA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"GB","regulator":"MHRA","status":"likely_approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null},{"country_code":"EU","regulator":"EMA","status":"pending","approval_date":null,"mah":"","brand_name_local":"","application_number":""}],"trialStats":{"total":4,"withResults":2},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:49:37.663339+00:00","fieldsConflicting":0,"overallConfidence":0.95},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}